Letrozole Alter

Letrozole, the active ingredient in Letrozole Alter, is an aromatase inhibitor presented as an oral tablet for oral use. It works by selectively inhibiting the aromatase enzyme, thereby reducing estrogen production, and is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. The medication is administered under medical supervision and forms part of standard endocrine therapy protocols for this patient population.

GNH USA supplies Letrozole Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Letrozole is used in the endocrine therapy pathway for hormone‑dependent breast cancer. - Hormone receptor‑positive breast cancer (early stage): reduces risk of recurrence by lowering estrogen levels. - Hormone receptor‑positive breast cancer (adjuvant setting): improves disease‑free survival when added to standard postoperative treatment. - Hormone receptor‑positive metastatic breast cancer: delays disease progression in postmenopausal patients.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Joint and muscle pain: arthralgia or myalgia affecting daily activities. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases or hepatitis. - Bone fracture: increased risk due to reduced bone mineral density. - Pulmonary embolism: sudden shortness of breath and chest pain. - Anaphylactic reaction: severe allergic response requiring emergency care.

When prescribing Letrozole, clinicians should observe several safety considerations. - Pregnancy contraindication: avoid use in pregnant women; teratogenic (Category X). - Bone health monitoring: assess bone mineral density periodically. - Liver function: evaluate hepatic enzymes before initiation and during treatment. - Cardiovascular risk: monitor for signs of thrombosis or hypertension. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Estrogen replacement therapy: may counteract aromatase inhibition and reduce therapeutic benefit. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly decrease letrozole plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect; monitor INR. - Statins (e.g., simvastatin): potential for increased muscle toxicity. - Antidepressants (e.g., fluoxetine): may alter letrozole metabolism; observe for side‑effect changes.